US 11597765
Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
granted A61KA61K2039/505A61K2039/6056
Quick answer
US patent 11597765 (Use of semaphorin-4D binding molecules for the treatment of Rett syndrome) held by VACCINEX, INC. expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- VACCINEX, INC.
- Grant date
- Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/6056, A61P, A61P25/00